Medpace Holdings, Inc.

MEDP - CIK 0001668397

Market cap$13.30 B

Rank#785

SEC filings874

Medpace Holdings, Inc. trades as MEDP and has a market capitalization of $13.30 B, making it the #785 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $2.53B, up 20.0% from the prior year and net income of $451.12M. This page tracks Medpace Holdings, Inc. through 874 SEC filings, with financial statements and metrics updated as new reports are filed.

Key metrics

Revenue (latest FY)$2.53BFY 2025

Net income (latest FY)$451.12MFY 2025

Operating cash flow (latest FY)$713.22MFY 2025

Total assets (latest FY)$1.98BFY 2025

Net margin17.8%latest FY

Financial performance

Over the last 9 fiscal years Medpace Holdings, Inc.'s revenue grew from $421.58M to $2.53B, a compound annual growth rate of 22.0%. Net profit margin expanded from 3.2% to 17.8% over the same period - every figure below comes from the company's audited annual filings.

MEDP annual revenueView details

Key statistics

Market cap: $13.30 B
Share price (derived)market cap / shares outstanding: $465.73
P/E ratio (trailing FY): 29.5
EPS (diluted)FY 2025: $15.28
Shares outstandingas of 2026-04-17: 0.03B
Total equityas of 2026-03-31: $598.31M
Return on equity: 75.4%
Cash & equivalentsas of 2026-03-31: $652.68M

Latest filings

Filing	Type	Filed
Major company event	8-K	2026-05-19
Insider trade	4	2026-05-18
Insider trade	4	2026-05-18
Insider trade	4	2026-05-18
Insider trade	4	2026-05-18
Insider trade	4	2026-05-18
Insider trade	4	2026-05-18
Insider trade	4	2026-04-28

Browse the full filing history (874 filings)

Recent press releases

Medpace Holdings, Inc. Reports First Quarter 2026 Results2026-04-22
Medpace Holdings, Inc. Reports First Quarter 2026 Results | Medpace Holdings, Inc.
Medpace Holdings, Inc. to Report First Quarter 2026 Financial Results on April 22, 20262026-04-22
Our mission is to accelerate the development of safe and effective medical therapeutics.
Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Results2026-02-09
Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Results | Medpace Holdings, Inc.
Medpace Holdings, Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 9, 20262026-02-09
Our mission is to accelerate the development of safe and effective medical therapeutics.
Medpace Holdings, Inc. to Report First Quarter 2026 Financial ...
(Nasdaq: MEDP) (“Medpace”) today announced that it will report its first quarter 2026 financial results after the market close on Wednesday, April 22, 2026 .

Similar companies

The largest companies sharing Medpace Holdings, Inc.'s SEC industry classification (services-commercial physical & biological research).

IQVIQVIA Holdings Inc.$30.40 B MEDP vs IQV

INCYIncyte Corporation$21.23 B MEDP vs INCY

ICLRICON Public Limited Company$11.04 B MEDP vs ICLR

CRLCharles River Laboratories International, Inc.$8.97 B MEDP vs CRL

ABSIAbsci Corporation$1.04 B MEDP vs ABSI

Frequently asked questions

What is Medpace Holdings, Inc.'s market cap?

Medpace Holdings, Inc. (MEDP) has a market capitalization of $13.30 B as of 2026-06-10, ranking #785 among US-listed companies.

How much revenue does Medpace Holdings, Inc. make?

Medpace Holdings, Inc. reported revenue of $2.53B for fiscal year 2025, an increase of 20.0% year over year.

Is Medpace Holdings, Inc. profitable?

Yes. Medpace Holdings, Inc. reported net income of $451.12M in its latest fiscal year.

Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.